This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates
by Zacks Equity Research
Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.
NVSPositive Net Change INCYPositive Net Change MESONegative Net Change ALXONegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
by Zacks Equity Research
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
REGNPositive Net Change SNYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs pharmaceuticals
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
by Zacks Equity Research
Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.
REGNPositive Net Change RHHBYPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology medical pharmaceuticals
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
by Zacks Equity Research
Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.
CGENNegative Net Change APLSNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
CGENNegative Net Change PTCTNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Top and Flop ETFs of the First Half
by Sweta Killa
We have highlighted three ETFs each from the best and worst-performing zones in the first half of 2024.
AMZNNegative Net Change AAPLNegative Net Change MSFTNegative Net Change NVDANegative Net Change VIXYNegative Net Change SMHNegative Net Change WBAPositive Net Change GBTCPositive Net Change SPMONegative Net Change PSILNegative Net Change LITPNegative Net Change
biotechnology bitcoin etfs semiconductor
Easterly Government Properties (DEA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DEANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
by Zacks Equity Research
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
CGENNegative Net Change COGTPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
by Zacks Equity Research
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
SNYPositive Net Change BIIBPositive Net Change DNLINegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
by Zacks Equity Research
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
MRKNegative Net Change CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
ALNYPositive Net Change ALIMPositive Net Change JAZZNegative Net Change SRPTPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
by Zacks Equity Research
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
RDYNegative Net Change ANVSNegative Net Change ALXONegative Net Change HLNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
by Zacks Equity Research
Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
NVONegative Net Change CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
by Kinjel Shah
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
VRTXPositive Net Change MRNANegative Net Change CRSPNegative Net Change
biotechnology
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
by Zacks Equity Research
CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.
CGENNegative Net Change CASIPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
by Zacks Equity Research
Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.
BAYRYNegative Net Change CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amicus (FOLD) stock based on the movements in the options market lately.
FOLDPositive Net Change
biotechnology biotechs medical
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
by Zacks Equity Research
ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.
CGENNegative Net Change ANVSNegative Net Change ALXONegative Net Change IBRXNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
by Zacks Equity Research
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
RHHBYPositive Net Change SRPTPositive Net Change NERVPositive Net Change ALXONegative Net Change
biotechnology biotechs
Best and Worst ETF Zones of Q2
by Sweta Killa
Technology remained the best-performing sector of the second quarter on the AI drive while energy lagged.
SLVPPositive Net Change UNGNo Net Change BDRYPositive Net Change PSILNegative Net Change WGMIPositive Net Change WEEDPositive Net Change
biotechnology bitcoin etfs marijuana
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
by Zacks Equity Research
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
NVONegative Net Change LLYPositive Net Change ANVSNegative Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
GHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Omega Healthcare Investors (OHI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
OHIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Chewy (CHWY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CHWYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
by Kinjel Shah
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.
BIIBPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechnology